AI in pharma supply chains fails when the data underneath it is incomplete, inconsistent, or impossible to trace. A model takes a wrong lane record at face value, scores it, and recommends on it with full confidence. Reliable data comes first: every lane, packaging, shipment, and partner record complete, current, and traceable to its source before any model touches it.
A data foundation is the set of records a model reads before it recommends anything. In pharma logistics that means lane, packaging, shipment, and partner records. Four properties make them usable: complete, consistent, current, and traceable to source.
The World Health Organization (WHO) sets a familiar bar for GxP records. Data should be attributable, legible, contemporaneous, original, and accurate, and also complete, consistent, enduring, and available (the ALCOA+ principles, WHO TRS 1033, Annex 4). Any record an AI model will read can be held to the same test.
Gartner frames the AI side of it. Data must represent the use case, including its patterns, errors, and outliers, and data with issues is not ready for AI (Gartner, February 2025).
Weak data shows up as small, plausible errors that a model then repeats at scale. Three scenes, illustrative composites built from common patterns:
One lane, three names. A Basel to Singapore lane sits in the system as “BSL-SIN,” “Basel > Singapore,” and a forwarder's route code. The model sees three thin histories where there should be one deep one. Each score rests on a fragment of the record.
A handover logged in the wrong time zone. A six-hour offset turns a 4-hour dwell into 10 hours, or hides a real 10-hour dwell. The recommendation that follows looks precise and runs on a wrong clock.
A score that changes overnight. A quality manager asks which input moved it. An auditor will ask the same. The answer exists only if every input carries its source.
EY's life sciences supply chain team lists the same flaws in pharma manufacturing data: silos, timestamp mismatches, inconsistent terminology, and poor data lineage among them. Its authors place the cause of stalled AI pilots in the readiness of the data, ahead of the model itself (EY, January 2026).
A model scales whatever it is given. Fed a clean record, it applies the same logic to ten thousand lanes at once. Fed a flawed one, it applies the flaw to ten thousand lanes at once.
The FDA's draft guidance on AI in drug development makes the dependency explicit: “The performance of an AI model relies heavily on the datasets used to train and tune the model.” It asks that data be fit for use, meaning relevant and reliable, and describes reliable data as accurate, complete, and traceable (FDA draft guidance, January 2025). The guidance addresses AI that supports regulatory decisions about drug safety, effectiveness, or quality. The same data principles are a sound bar for any AI-supported decision in a regulated supply chain.
The readiness gap is wide. In a Gartner survey of 1,203 data management leaders (July 2024), 63% said their organizations either lack the right data management practices for AI or are unsure whether they have them. Gartner predicts that through 2026, organizations will abandon 60% of AI projects unsupported by AI-ready data (Gartner, February 2025).
Five things, in the order they pay off:
EY's authors recommend starting small: pick one pressing problem, fix its data, then apply AI to it (EY, January 2026). A single lane portfolio is a workable place to begin.
Validaide structures the work that creates the data. Every lane risk assessment follows the same method, so a lane assessed in Basel and one assessed in Singapore are described in the same terms. The platform has digitized and assessed more than 70,000 lanes, and each assessment adds to a shared record.
The Dynamic Pharma Index scores lanes from real shipment performance and incident history, alongside temperature exposure, packaging protection, supplier quality, security, and route complexity. Shipment data from loggers and external sources flows into the same lane record, so the score reflects what happened on the lane as well as what was planned for it. The index draws on verified data from 2,094 qualified suppliers.
Connection matters as much as structure. Six of the top 10 pharma companies use Validaide, and all of the top 20 freight forwarders are connected. When shippers and forwarders work from one lane record, the definitions stay aligned across partners.
Where AI supports a decision, the inputs trace back to those records. For how the pieces fit together, see what pharmaceutical supply chain orchestration is and how to build a data-driven cold chain risk program.
Simulation and scoring inform a decision. Each regulated shipment still needs its own validation.
AI in pharma supply chains fails when its data is incomplete, inconsistent, or untraceable. The questions below cover what a reliable data foundation takes and how Validaide supports it.
Most failures trace back to the data. When lane, packaging, location, or shipment records are incomplete, inconsistent, or untraceable, a model scores them anyway and returns confident output. Gartner predicts organizations will abandon 60% of AI projects unsupported by AI-ready data through 2026.
It is the set of records a model reads before it recommends anything. In pharma logistics, that means lane, packaging, shipment, and partner data that is complete, consistent, current, and traceable to its source.
Gartner describes it as data that represents the use case, including its patterns, errors, and outliers, with metadata that governs it. Data with issues is not ready for AI.
AI can flag some anomalies. Fixing the cause means correcting definitions, ownership, and source records upstream. A model trained or run on flawed records carries the flaws into every score.
Pick one lane portfolio, standardize how its lanes are defined and assessed, and confirm that position and time data are verified. Apply AI to that portfolio first.
Validaide applies one assessment method across lanes, connects shippers and forwarders on a shared lane record, and feeds shipment performance back into the Dynamic Pharma Index. More than 70,000 lanes are digitized and assessed on the platform.
This article was written by Médb Kiely-Cuddy, Validaide’s content specialist, with assistance from generative AI. All content and facts were reviewed by a human before publication.